Abstract
The iboga alkaloids are a class of naturally occurring and synthetic compounds, some of which modify drug self-administration and withdrawal in humans and preclinical models. Ibogaine, the prototypic iboga alkaloid that is utilized clinically to treat addictions, has been associated with QT prolongation, torsades de pointes and fatalities. hERG blockade as IKr was measured using the whole-cell patch clamp technique in HEK 293 cells. This yielded the following IC50 values: ibogaine manufactured by semisynthesis via voacangine (4.09 ± 0.69 µM) or by extraction from T. iboga (3.53 ± 0.16 µM); ibogaine’s principal metabolite noribogaine (2.86 ± 0.68 µM); and voacangine (2.25 ± 0.34 µM). In contrast, the IC50 of 18-methoxycoronaridine, a product of rational synthesis and current focus of drug development was >50 µM. hERG blockade was voltage dependent for all of the compounds, consistent with low-affinity blockade. hERG channel binding affinities (K i) for the entire set of compounds, including 18-MC, ranged from 0.71 to 3.89 µM, suggesting that 18-MC binds to the hERG channel with affinity similar to the other compounds, but the interaction produces substantially less hERG blockade. In view of the extended half-life of noribogaine, these results may relate to observations of persistent QT prolongation and cardiac arrhythmia at delayed intervals of days following ibogaine ingestion. The apparent structure–activity relationships regarding positions of substitutions on the ibogamine skeleton suggest that the iboga alkaloids might provide an informative paradigm for investigation of the structural biology of the hERG channel.
Similar content being viewed by others
References
Bartlett, M. F., Dickel, D. F., & Taylor, W. I. (1958). The alkaloids of Tabernanthe-Iboga. Part VI. The Structures of ibogamine, ibogaine, tabernanthine and voacangine. Journal of the American Chemical Society, 80, 126–136.
Jana, G. K., Paul, S., & Sinha, S. (2011). Progress in the synthesis of iboga-alkaloids and their congeners. Organic Preparations and Procedures International, 43, 541–573.
Alper, K. R. (2001). Ibogaine: A review. The Alkaloids: Chemistry and Biology, 56, 1–38.
Glick, S. D., Maisonneuve, I. M., & Szumlinski, K. K. (2001). Mechanisms of action of ibogaine: Relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. The Alkaloids: Chemistry and Biology, 56, 39–53.
Alper, K. R., Lotsof, H. S., & Kaplan, C. D. (2008). The ibogaine medical subculture. Journal of Ethnopharmacology, 115, 9–24.
Vastag, B. (2005). Addiction research. Ibogaine therapy: A ‘vast, uncontrolled experiment’. Science, 308, 345–346.
Antonio, T., Childers, S. R., Rothman, R. B., Dersch, C. M., King, C., Kuehne, M., et al. (2013). Effect of iboga alkaloids on μ-opioid receptor-coupled G protein activation. PLoS ONE, 8, e77262.
National Institutes of Health. (2014). IND-Enabling Studies and GMP Scale-Up of 18-Methoxycoronaridine Hydrochloride (18 MC) Project Number: 1U01DA034986-01. http://projectreporter.nih.gov/project_info_description.cfm?aid=8448461&icde=16047111&ddparam=&ddvalue=&ddsub=&cr=41&csb=default&cs=ASC. Accessed January 05, 2015.
Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R., Ervin, F. R., Kamlet, J. D., & Hearn, W. L. (2001). Ibogaine in the treatment of heroin withdrawal. The Alkaloids: Chemistry and Biology, 56, 155–171.
Alper, K. R., Lotsof, H. S., Frenken, G. M., Luciano, D. J., & Bastiaans, J. (1999). Treatment of acute opioid withdrawal with ibogaine. The American Journal on Addictions, 8, 234–242.
Alper, K. R., Stajic, M., & Gill, J. R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57, 398–412.
Hoelen, D. W., Spiering, W., & Valk, G. D. (2009). Long-QT syndrome induced by the antiaddiction drug ibogaine. New England Journal of Medicine, 360, 308–309.
Pleskovic, A., Gorjup, V., Brvar, M., & Kozelj, G. (2012). Ibogaine-associated ventricular tachyarrhythmias. Clinical Toxicology, 50, 157.
Dettmer, M. R., Cohn, B., & Schwarz, E. (2013). Prolonged QTc and ventricular tachycardia after ibogaine ingestion [(XXXIII International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT)). Clinical Toxicology, 51, 285.
Heling, D., Strassburg, C. P., & Wasmuth, J. C. (2014). Tod nach lbogain-Einnahme- Vergiftung durch Entgiftung (Death after ibogaine consumption—Intoxication by detoxification). Intensiv- und Notfallbehandlung, 39, 40–43.
Shawn, L. K., Alper, K., Desai, S. P., Stephenson, K., Olgun, A. M., Nelson, L. S., & Hoffman, R. S. (2012). Pause-dependent ventricular tachycardia and torsades de pointes after ibogaine ingestion [2012 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT)]. Clinical Toxicology, 50, 654.
Kannankeril, P., Roden, D. M., & Darbar, D. (2010). Drug-induced long QT syndrome. Pharmacological Reviews, 62, 760–781.
Sanguinetti, M. C., & Tristani-Firouzi, M. (2006). hERG potassium channels and cardiac arrhythmia. Nature, 440, 463–469.
Koenig, X., Kovar, M., Boehm, S., Sandtner, W., & Hilber, K. (2014). Anti-addiction drug ibogaine inhibits hERG channels: A cardiac arrhythmia risk. Addiction Biology, 19, 237–239.
Thurner, P., Stary-Weinzinger, A., Gafar, H., Gawali, V. S., Kudlacek, O., Zezula, J., et al. (2014). Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine. Journal of Pharmacology and Experimental Therapeutics, 348, 346–358.
Kontrimavičiūtė, V., Mathieu, O., Mathieu-Daudé, J. C., Vainauskas, P., Casper, T., Baccino, E., & Bressolle, F. M. (2006). Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub. Journal of Analytical Toxicology, 30, 434–440.
Mash, D. C., Kovera, C. A., Buck, B. E., Norenberg, M. D., Shapshak, P., Hearn, W. L., & Sanchez-Ramos, J. (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. Annals of the New York Academy of Sciences, 844, 274–292.
Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R. F., Ervin, F. D., Williams, I. C., et al. (2000). Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences, 914, 394–401.
Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C. T., & Friedhoff, L. (2014). Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. The Journal of Clinical Pharmacology,. doi:10.1002/jcph.1404.
Koenig, X., Kovar, M., Rubi, L., Mike, A. K., Lukacs, P., Gawali, V. S., et al. (2013). Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug’s cardiac ion channel profile. Toxicology and Applied Pharmacology, 273, 259–268.
Huang, X. P., Mangano, T., Hufeisen, S., Setola, V., & Roth, B. L. (2010). Identification of human Ether-a-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay and Drug Development Technologies, 8, 727–742.
Roth, B. L. (2013). National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) assay protocol book version II. Chapel Hill, NC: Department of Pharmacology, University of North Carolina at Chapel Hill.
Warrick, B., & Baltarowich, L. (2012). Ibogaine for opioid addiction: A deadly treatment [2012 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT)]. Clinical Toxicology, 50, 656.
Jalal, S., Daher, E., & Hilu, R. (2013). A case of death due to ibogaine use for heroin addiction: Case report. The American Journal on Addictions, 22, 302.
Roden, D. M. (1998). Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes. Pacing and Clinical Electrophysiology, 21, 1029–1034.
Cubeddu, L. X. (2009). Iatrogenic QT abnormalities and fatal arrhythmias: Mechanisms and clinical significance. Current Cardiology Reviews, 5, 166–176.
Levin, K. H., Copersino, M. L., Epstein, D., Boyd, S. J., & Gorelick, D. A. (2008). Longitudinal ECG changes in cocaine users during extended abstinence. Drug and Alcohol Dependence, 95, 160–163.
Otero-Anton, E., Gonzalez-Quintela, A., Saborido, J., Torre, J. A., Virgos, A., & Barrio, E. (1997). Prolongation of the QTc interval during alcohol withdrawal syndrome. Acta Cardiologica, 52, 285–294.
Vlaanderen, L., Martial, L. C., Franssen, E. J. F., van der Voort, P. H. J., Oosterwerff, E., & Somsen, G. A. (2014). Cardiac arrest after ibogaine ingestion. Clinical Toxicology, 52, 642–643.
Dhahir, H. I. (1971). A comparative study on the toxicity of ibogaine and serotonin (p. 163). Bloomington: Indiana University.
Glick, S. D., Maisonneuve, I. M., Hough, L. B., Kuehne, M. E., & Bandarage, U. K. (1999). (±)-18-Methoxycoronaridine: A novel iboga alkaloid congener having potential anti-addictive efficacy. CNS Drug Reviews, 5, 27–42.
Binienda, Z. K., Pereira, F., Alper, K., Slikker, W, Jr, & Ali, S. F. (2002). Adaptation to repeated cocaine administration in rats. Annals of the New York Academy of Sciences, 965, 172–179.
Schneider, J. A., & Rinehart, R. K. (1957). Analysis of the cardiovascular action of ibogaine hydrochloride. Archives Internationales de Pharmacodynamie et de Therapie, 110, 92–102.
Mash, D. C., Allen-Ferdinand, K., Mayor, M., Kovera, C. A., Ayafor, J. F., Williams, I. C., et al. (1998). Ibogaine: Clinical observations of safety after single oral dose administrations. In Problems of drug dependence, 1998: Proceedings of the 60th annual scientific meeting, June 12–17 (p. 294). Scottsdale, Arizona: The College on Problems of Drug Dependence, Inc.
Samorini, G. (1998). The initiation rite in the Bwiti Religion (Ndea Narizanga Sect, Gabon). Jahrbuch für Ethnomedizin und Bewusstseinsforschung, 6–7, 39–56.
Alper, K., Reith, M. E. A., & Sershen, H. (2012). Ibogaine and the inhibition of acetylcholinesterase. Journal of Ethnopharmacology, 139, 879–882.
Kolecki, P. F., & Curry, S. C. (1997). Poisoning by sodium channel blocking agents. Critical Care Clinics, 13, 829–848.
Sanchez-Chapula, J. A., Navarro-Polanco, R. A., Culberson, C., Chen, J., & Sanguinetti, M. C. (2002). Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. Journal of Biological Chemistry, 277, 23587–23595.
Le Men, L., & Taylor, W. I. (1965). A uniform numbering system for indole alkaloids. Experientia, 21, 508–510.
Alper, K. R., & Cordell, G. A. (2001). A note concerning the numbering of the iboga alkaloids. In Ibogaine: Proceedings of the first international conference (also published as The Alkaloids Chemistry and Biology Vol. 56) (Alper, K. R., Glick, S. D., & Cordell, G. A., eds), pp. xxiii–xxiv. San Diego: Academic Press.
Coi, A., Massarelli, I., Testai, L., Calderone, V., & Bianucci, A. M. (2008). Identification of “toxicophoric” features for predicting drug-induced QT interval prolongation. European Journal of Medicinal Chemistry, 43, 2479–2488.
Yan, G. X., Wu, Y., Liu, T., Wang, J., Marinchak, R. A., & Kowey, P. R. (2001). Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : Direct evidence from intracellular recordings in the intact left ventricular wall. Circulation, 103, 2851–2856.
Bai, R., Lu, J. G., Pu, L., Liu, N., Zhou, Q., Ruan, Y. F., et al. (2005). Left ventricular epicardial activation increases transmural dispersion of repolarization in healthy, long QT, and dilated cardiomyopathy dogs. PACE-Pacing Clinical Electrophysiology, 28, 1098–1106.
Wang, L., Lu, J., Zhang, F., Bai, R., & Wang, L. (2006). Effects of amiodarone on transmural dispersion of ventricular effective refractory periods across myocardial layers in the normal and hypertrophic canine heart. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 26, 182–184.
Acknowledgements
Drs. Rong Bai and Nian Liu were supported by the National Natural Science Foundation of China (NSFC-81370290 and NSFC-81370292). We thank Stevenson Flemer and Bruce O’Rourke from the University of Vermont for HPLC/MS analyses. We thank Dr. Maarten E. A. Reith and Dr. Dave Nichols for helpful discussion and Reith Lab for logistical support regarding the research compounds.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alper, K., Bai, R., Liu, N. et al. hERG Blockade by Iboga Alkaloids. Cardiovasc Toxicol 16, 14–22 (2016). https://doi.org/10.1007/s12012-015-9311-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-015-9311-5